Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration. The trial investigated the safety,
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...
IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...
Novo Nordisk shares surged on the results of a new obesity-drug study Friday. The Danish pharmaceutical giant behind Ozempic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback